ObsEva SA (NASDAQ:OBSV) – Analysts at Leerink Swann lifted their FY2017 earnings per share estimates for ObsEva SA in a research report issued to clients and investors on Tuesday. Leerink Swann analyst P. Matteis now expects that the company will earn ($2.25) per share for the year, up from their prior estimate of ($2.57). Leerink Swann currently has a “Outperform” rating and a $18.00 target price on the stock. Leerink Swann also issued estimates for ObsEva SA’s Q4 2017 earnings at ($0.48) EPS, Q1 2018 earnings at ($0.54) EPS, Q2 2018 earnings at ($0.58) EPS, Q3 2018 earnings at ($0.63) EPS, Q4 2018 earnings at ($0.69) EPS, FY2018 earnings at ($2.45) EPS, FY2019 earnings at ($2.50) EPS and FY2020 earnings at ($2.60) EPS.
ObsEva SA (NASDAQ:OBSV) last announced its quarterly earnings results on Tuesday, November 14th. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.01). The firm’s quarterly revenue was up NaN% on a year-over-year basis. ILLEGAL ACTIVITY NOTICE: “FY2017 EPS Estimates for ObsEva SA Increased by Leerink Swann (OBSV)” was first posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at https://ledgergazette.com/2017/11/17/fy2017-eps-estimates-for-obseva-sa-increased-by-leerink-swann-obsv.html.
OBSV has been the topic of several other reports. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price target on shares of ObsEva SA in a research report on Wednesday, November 8th. Royal Bank Of Canada reaffirmed a “buy” rating and set a $22.00 price target on shares of ObsEva SA in a research report on Thursday, November 2nd. Zacks Investment Research upgraded ObsEva SA from a “sell” rating to a “hold” rating in a research report on Friday, September 8th. Finally, Credit Suisse Group began coverage on ObsEva SA in a research report on Monday, October 9th. They set an “outperform” rating and a $16.00 target price on the stock. Six research analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and a consensus target price of $18.83.
Shares of ObsEva SA (NASDAQ:OBSV) traded up $0.14 on Friday, reaching $11.30. The company’s stock had a trading volume of 25,263 shares, compared to its average volume of 45,655. ObsEva SA has a 12 month low of $5.00 and a 12 month high of $14.69.
Several large investors have recently bought and sold shares of the company. VHCP Management II LLC grew its position in shares of ObsEva SA by 834.2% during the 3rd quarter. VHCP Management II LLC now owns 1,401,343 shares of the company’s stock valued at $11,407,000 after acquiring an additional 1,251,343 shares during the period. Abingworth LLP acquired a new stake in ObsEva SA in the 3rd quarter worth about $3,480,000. Sphera Funds Management LTD. boosted its holdings in ObsEva SA by 12.4% in the 3rd quarter. Sphera Funds Management LTD. now owns 260,197 shares of the company’s stock worth $2,118,000 after buying an additional 28,700 shares during the last quarter. Sectoral Asset Management Inc boosted its holdings in ObsEva SA by 181.9% in the 2nd quarter. Sectoral Asset Management Inc now owns 212,831 shares of the company’s stock worth $1,820,000 after buying an additional 137,331 shares during the last quarter. Finally, Iguana Healthcare Management LLC boosted its holdings in ObsEva SA by 66.7% in the 3rd quarter. Iguana Healthcare Management LLC now owns 50,000 shares of the company’s stock worth $407,000 after buying an additional 20,000 shares during the last quarter. Hedge funds and other institutional investors own 48.46% of the company’s stock.
About ObsEva SA
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.
Receive News & Ratings for ObsEva SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva SA and related companies with MarketBeat.com's FREE daily email newsletter.